When we assessed GUCY1B1 gene expression across a wider panel of baseline CDX models (derived from patients before their treatment), there was no correlation between GUCY1B1 expression and the subsequent chemotherapy response of patient donors, suggesting that pre-treatment sGC expression levels do not signpost inherent, chemorefractory disease (Fig. 2e). Here, SGCB is linked to glycogen storage disease VI.